Posted by Michael Wonder on 28 Sep 2020
ICER publishes white paper on cornerstones for fair patient access to prescription drugs, launches annual assessment of US payer policies
28 September 2020 - Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, white paper provides recommendations for appropriate design and implementation of policies that determine patient access to prescription drugs.
The Institute for Clinical and Economic Review (ICER), in collaboration with researchers at the Office of Health Economics (OHE), has published a new white paper: “Cornerstones of ‘Fair’ Drug Coverage: Appropriate Cost-Sharing and Utilization Management Policies for Pharmaceuticals.”
The purpose of the white paper is to analyse the ethical and practical dimensions of insurance coverage policy, while presenting a corresponding set of criteria that will support a more transparent discussion among all health care stakeholders about whether specific cost sharing and utilisation management policies are delivering “fair” patient access to prescription drugs.
